172 related articles for article (PubMed ID: 19505376)
1. Quantity, distribution and immunophenotypical modification of dendritic cells upon biological treatments in psoriasis.
Prignano F; Ricceri F; Bianchi B; Lotti T
Int J Immunopathol Pharmacol; 2009; 22(2):379-87. PubMed ID: 19505376
[TBL] [Abstract][Full Text] [Related]
2. TNFalpha and its receptors in psoriatic skin, before and after treatment with etanercept.
Caldarola G; De Simone C; Carbone A; Tulli A; Amerio P; Feliciani C
Int J Immunopathol Pharmacol; 2009; 22(4):961-6. PubMed ID: 20074459
[TBL] [Abstract][Full Text] [Related]
3. Effects of TNF-alpha inhibitors on the number of epidermal Langerhans cells in uninvolved skin of psoriatic patients: a pilot study.
Piaserico S; Zattra E; Michelotto A; Alaibac M
Acta Histochem; 2013 Sep; 115(7):767-9. PubMed ID: 23566554
[TBL] [Abstract][Full Text] [Related]
4. Reduction of inflammatory slan (6-sulfo LacNAc) dendritic cells in psoriatic skin of patients treated with etanercept.
Günther C; Blau K; Förster U; Viehweg A; Wozel G; Schäkel K
Exp Dermatol; 2013 Aug; 22(8):535-40. PubMed ID: 23879812
[TBL] [Abstract][Full Text] [Related]
5. Angiogenesis in psoriatic skin and its modifications after administration of etanercept: videocapillaroscopic, histological and immunohistochemical evaluation.
Campanati A; Goteri G; Simonetti O; Ganzetti G; Giuliodori K; Giuliano A; Sabato S; Stramazzotti D; Gulini E; Dusi D; De Blasio S; Fabris G; Offidani A
Int J Immunopathol Pharmacol; 2009; 22(2):371-7. PubMed ID: 19505391
[TBL] [Abstract][Full Text] [Related]
6. Relevance of compartmentalization of T-cell subsets for clinical improvement in psoriasis: effect of immune-targeted antipsoriatic therapies.
van Lingen RG; Körver JE; van de Kerkhof PC; Berends MA; van Rens DW; Langewouters AM; Boezeman JB; Seyger MM; de Jong EM
Br J Dermatol; 2008 Jul; 159(1):91-6. PubMed ID: 18476954
[TBL] [Abstract][Full Text] [Related]
7. Targeting TNFalpha rapidly reduces density of dendritic cells and macrophages in psoriatic plaques with restoration of epidermal keratinocyte differentiation.
Marble DJ; Gordon KB; Nickoloff BJ
J Dermatol Sci; 2007 Nov; 48(2):87-101. PubMed ID: 17689932
[TBL] [Abstract][Full Text] [Related]
8. Immunophenotyping of dendritic cells in lesional, perilesional and distant skin of chronic plaque psoriasis.
Alshenawy HA; Hasby EA
Cell Immunol; 2011; 269(2):115-9. PubMed ID: 21470599
[TBL] [Abstract][Full Text] [Related]
9. Effective treatment of psoriasis with etanercept is linked to suppression of IL-17 signaling, not immediate response TNF genes.
Zaba LC; Suárez-Fariñas M; Fuentes-Duculan J; Nograles KE; Guttman-Yassky E; Cardinale I; Lowes MA; Krueger JG
J Allergy Clin Immunol; 2009 Nov; 124(5):1022-10.e1-395. PubMed ID: 19895991
[TBL] [Abstract][Full Text] [Related]
10. Etanercept induces apoptosis of dermal dendritic cells in psoriatic plaques of responding patients.
Malaviya R; Sun Y; Tan JK; Wang A; Magliocco M; Yao M; Krueger JG; Gottlieb AB
J Am Acad Dermatol; 2006 Oct; 55(4):590-7. PubMed ID: 17010737
[TBL] [Abstract][Full Text] [Related]
11. TNF inhibition rapidly down-regulates multiple proinflammatory pathways in psoriasis plaques.
Gottlieb AB; Chamian F; Masud S; Cardinale I; Abello MV; Lowes MA; Chen F; Magliocco M; Krueger JG
J Immunol; 2005 Aug; 175(4):2721-9. PubMed ID: 16081850
[TBL] [Abstract][Full Text] [Related]
12. Immunologic targets in psoriasis.
Kupper TS
N Engl J Med; 2003 Nov; 349(21):1987-90. PubMed ID: 14627782
[No Abstract] [Full Text] [Related]
13. Sun exposure rapidly reduces plasmacytoid dendritic cells and inflammatory dermal dendritic cells in psoriatic skin.
Heier I; Søyland E; Krogstad AL; Rodríguez-Gallego C; Nenseter MS; Jahnsen FL
Br J Dermatol; 2011 Oct; 165(4):792-801. PubMed ID: 21623747
[TBL] [Abstract][Full Text] [Related]
14. Density of epidermal Langerhans cells in psoriasis patients treated with an aromatic retinoid (RO 10-9359). An immunoperoxidase study using anti-T6 and anti-Ia monoclonal antibodies.
Guzman de Fleury M; Tapia FJ; Soto J; Ghersi N; Convit J
Histol Histopathol; 1986 Jul; 1(3):227-34. PubMed ID: 2856536
[TBL] [Abstract][Full Text] [Related]
15. Cytomegalovirus complicating biological immunosuppressive therapy in two patients with psoriasis receiving treatment with etanercept or efalizumab.
Petersen B; Lorentzen H
Acta Derm Venereol; 2008; 88(5):523-4. PubMed ID: 18779901
[No Abstract] [Full Text] [Related]
16. Inhibition of CCR7/CCL19 axis in lesional skin is a critical event for clinical remission induced by TNF blockade in patients with psoriasis.
Bosè F; Petti L; Diani M; Moscheni C; Molteni S; Altomare A; Rossi RL; Talarico D; Fontana R; Russo V; Altomare G; Reali E
Am J Pathol; 2013 Aug; 183(2):413-21. PubMed ID: 23731727
[TBL] [Abstract][Full Text] [Related]
17. Etanercept for psoriasis: two case reports.
Fidalgo A; Baptista J; Rocha Páris F; Caldas Lopes L; Ferreira A
Int J Clin Pharmacol Res; 2005; 25(4):159-63. PubMed ID: 16402631
[TBL] [Abstract][Full Text] [Related]
18. Antitumour necrosis factor-alpha chimeric antibody (infliximab) inhibits activation of skin-homing CD4+ and CD8+ T lymphocytes and impairs dendritic cell function.
Bedini C; Nasorri F; Girolomoni G; Pità Od; Cavani A
Br J Dermatol; 2007 Aug; 157(2):249-58. PubMed ID: 17489975
[TBL] [Abstract][Full Text] [Related]
19. Biologic therapies in psoriasis: a new therapeutic approach.
Gisondi P; Girolomoni G
Autoimmun Rev; 2007 Sep; 6(8):515-9. PubMed ID: 17854741
[TBL] [Abstract][Full Text] [Related]
20. Adverse reactions during biological drug therapy in psoriasis:clinical series and a review of the literature.
Montesu MA; Addis GM; Satta R; Cottoni F
G Ital Dermatol Venereol; 2011 Aug; 146(4):273-81. PubMed ID: 21785393
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
